Lukas Hainz

Lukas Hainz

Biopharma Innovation Specialist
Lukas Hainz specializes in biopharmaceutical research and development. He unpacks research from clinical trials and explores regulatory affairs implications on the pharmaceutical industry, focusing on innovative therapies and patent development.
Imipridones and Standard Treatment Show Promise for Glioblastoma
Research & Development Imipridones and Standard Treatment Show Promise for Glioblastoma

Glioblastoma, one of the most aggressive and treatment-resistant forms of brain cancer, presents a dire prognosis even with current standard treatment regimens including surgery, radiation, and the chemotherapy drug temozolomide (TMZ). However, a groundbreaking study published in Volume 16 of

Ultrasound and Bubbles: Singapore Trials Non-Invasive Tumor Treatment
Research & Development Ultrasound and Bubbles: Singapore Trials Non-Invasive Tumor Treatment

As a promising new frontier in cancer treatment, histotripsy represents a significant advancement in non-invasive medical procedures aimed at eliminating tumors. The technique utilizes bubbles generated via precise ultrasound waves to target and destroy specific cancer cells. Notably, histotripsy

Can Relacorilant and Nab-Paclitaxel Change Ovarian Cancer Treatment?
Research & Development Can Relacorilant and Nab-Paclitaxel Change Ovarian Cancer Treatment?

The recent results from the pivotal Phase 3 ROSELLA trial mark a significant development in the battle against platinum-resistant ovarian cancer. Corcept Therapeutics announced that the trial successfully demonstrated the efficacy of combining relacorilant with nab-paclitaxel chemotherapy,

How Is Synthetic Biology Revolutionizing Life Sciences at UD?
Biotech & Bioprocessing How Is Synthetic Biology Revolutionizing Life Sciences at UD?

The field of synthetic biology is experiencing rapid growth, merging principles from biology, engineering, chemistry, physics, and mathematics to unlock new potential in life sciences. At the forefront of this advancement is the University of Delaware (UD), where cutting-edge research is aimed at

Can AI Improve Diabetic Retinopathy and Macular Degeneration Screening?
Tech & Innovation Can AI Improve Diabetic Retinopathy and Macular Degeneration Screening?

Medical advancements are progressing rapidly, and one of the most promising areas is artificial intelligence (AI) in diagnostic imaging. AI technology has the potential to revolutionize healthcare by enhancing the accuracy and efficiency of diagnoses. Acer Medical recently introduced two

Can AI Chatbots Like Therabot Revolutionize Mental Health Treatment?
Tech & Innovation Can AI Chatbots Like Therabot Revolutionize Mental Health Treatment?

In an age where artificial intelligence continues to pervade every aspect of daily life, the idea of AI chatbots stepping into the realm of psychotherapy is no longer a far-fetched concept. Imagine reaching a point where a simple conversation with a machine could lessen the burden of your anxieties

Is Merck's $2B Deal with Hengrui a Game-Changer for Cardiometabolic Drugs?
Research & Development Is Merck's $2B Deal with Hengrui a Game-Changer for Cardiometabolic Drugs?

The pharmaceutical landscape is rapidly evolving, and at the forefront of these advancements is Merck & Co.'s groundbreaking licensing agreement with Jiangsu Hengrui Pharmaceuticals, focusing on the innovative Lipoprotein(a) [Lp(a)] inhibitor, HRS-5346. This monumental $2 billion deal puts

How Can We Improve Access and Reimbursement for Precision Medicine?
Tech & Innovation How Can We Improve Access and Reimbursement for Precision Medicine?

Precision medicine offers significant promise in enabling targeted therapies for complex illnesses, making treatment more effective and patient-centered. However, the process of facilitating access and reimbursement for these therapies presents unique challenges. Unlike the more predictable path of

New National Health Rules Enhance Privacy for Medicare and PBS Data
Management & Regulatory New National Health Rules Enhance Privacy for Medicare and PBS Data

The introduction of the National Health (Privacy) Rules 2025 marks a significant shift in the privacy settings governing the handling of Medicare Benefits Schedule (MBS) and Pharmaceutical Benefits Schedule (PBS) claims information by Australian Government agencies. Taking effect on April 1, 2025,

Advancements of AI Revolutionize Diagnostics and Treatment in Healthcare
Tech & Innovation Advancements of AI Revolutionize Diagnostics and Treatment in Healthcare

Artificial intelligence (AI) and machine learning (ML) represent transformative forces in modern healthcare that are unlocking unprecedented opportunities to improve diagnostic accuracy and optimize treatment plans. By integrating these sophisticated technologies into clinical practice, the

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later